New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that the Vision Transformer, an open-source computer vision algorithm, could detect changes in nailfold capillaroscopy images from systemic sclerosis patients.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, described a first-of-its-kind validated tool to screen for systemic sclerosis-associated interstitial lung disease.
A substance produced by gut microorganisms can lead to scarring and blood vessel damage in patients with scleroderma, a new study suggests. Researchers say they will examine whether drugs or food products, like virgin olive oil, can block the formation of the compound in the gut to treat fibrosis.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that use of platelet inhibitors could be associated with a reduction in the occurrence of digital ulcers in people with systemic sclerosis.
Researchers have discovered a protein that may predict disease severity for scleroderma-associated interstitial lung disease, the leading cause of death for patients with the rare autoimmune condition. Higher circulating levels of the CTRP9 were associated with more severe lung disease, while low levels were associated with preserved function.
People with the rare autoimmune disease scleroderma, who likely experience more serious isolation during a global pandemic, saw their anxiety and depression improve after receiving online mental health intervention through an international study. Researchers say the support program could be extended to many vulnerable patient populations moving forward.
April 8, 2021 – The Division of Rheumatology, Department of Medicine, Faculty of Medicine (CU Medi), Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society (Chulalongkorn Hospital), in collaboration with the Departments of Hematology, Pulmonary and Critical Care Medicine, and Infectious diseases, held a press conference on “Thailand’s first successful treatment of systemic sclerosis patients with pulmonary fibrosis by stem cell transplantation“.
A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.
Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.